Literature DB >> 10460625

An atypical myelodysplastic syndrome with t(9;12)(q22;p12) and TEL gene rearrangement.

Y Kuno, A Abe, N Emi, M Iida, T Yamamori, M Tanimoto, H Saito.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10460625     DOI： 10.1046/j.1365-2141.1999.01607.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  4 in total

Review 1.  [Protein-dysregulation in human and murine myeloproliferative neoplasms].

Authors:  K Aumann
Journal:  Pathologe       Date:  2018-12       Impact factor: 1.011

2.  Depletion of STAT5 blocks TEL-SYK-induced APMF-type leukemia with myelofibrosis and myelodysplasia in mice.

Authors:  C Sprissler; D Belenki; H Maurer; K Aumann; D Pfeifer; C Klein; T A Müller; S Kissel; J Hülsdünker; J Alexandrovski; T Brummer; H Jumaa; J Duyster; C Dierks
Journal:  Blood Cancer J       Date:  2014-08-22       Impact factor: 11.037

Review 3.  Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy.

Authors:  Ellen Weisberg; Martin Sattler; Paul W Manley; James D Griffin
Journal:  Onco Targets Ther       Date:  2017-12-29       Impact factor: 4.147

4.  Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase.

Authors:  Ellen L Weisberg; Alexandre Puissant; Richard Stone; Martin Sattler; Sara J Buhrlage; Jing Yang; Paul W Manley; Chengcheng Meng; Michael Buonopane; John F Daley; Suzan Lazo; Renee Wright; David M Weinstock; Amanda L Christie; Kimberly Stegmaier; James D Griffin
Journal:  Oncotarget       Date:  2017-07-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.